Lv4
442 积分 2023-09-30 加入
Inhibition of PCSK9 Improves the Development of Pulmonary Arterial Hypertension Via Down-Regulating Notch3 Expression
12天前
已完结
Pulmonary hypertension in interstitial lung disease and in chronic obstructive pulmonary disease: different entities?
1个月前
已完结
Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management
1个月前
已完结
Dehydrozingerone alleviates pulmonary fibrosis via inhibition of inflammation and epithelial-mesenchymal transition by regulating the Wnt/β-catenin pathway
1个月前
已完结
The pleiotropic effects of PCSK9 in cardiovascular diseases beyond cholesterol metabolism
1个月前
已完结
Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases
1个月前
已完结
Potential for inhibition of checkpoint kinases 1/2 in pulmonary fibrosis and secondary pulmonary hypertension
1个月前
已完结
Interstitial Lung Disease
1个月前
已完结
Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
1个月前
已完结
Impairment of the NKT–STAT1–CXCL9 Axis Contributes to Vessel Fibrosis in Pulmonary Hypertension Caused by Lung Fibrosis
2个月前
已完结
皖公网安备34019202002308
